Latest news with #UnitedHealthGroup
CNBC
4 hours ago
- Health
- CNBC
Taking on Goliath: Brain surgeon's clash with UnitedHealthcare shows insurer's hardball tactics
Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice in New Jersey that treats low-income children on Medicaid. Since 2008, she has cared for boys and girls with cerebral palsy, spina bifida and other neurological disorders. But now, her practice is in serious jeopardy, she says, because of recent moves by the insurance and health care giant UnitedHealth Group. The story begins in February 2024, when a unit of UnitedHealth experienced a massive hack. The unit, Change Healthcare, shuttered its systems and halted all reimbursements owed to hospitals and doctors like Mazzola. To help providers stay afloat, Optum, another UnitedHealth subsidiary that includes a bank, began offering "temporary," no-interest loans. Mazzola's practice was among those tapping into the program — it received $535,000, documents show. The practice began repaying the loans, but in January Optum demanded that it repay the money in full and within five business days. "Our practice is doing the BEST we can," Mazzola wrote in an email to Optum on Jan. 20. "Please ask the loan collection people to STOP. We are already in repayment at the maximum possible amount monthly." The situation soon got worse. In mid-February, she stopped receiving reimbursements from UnitedHealthcare. By April, her practice was out $78,000, her accountant's records show, and was struggling to make payroll. Mazzola dug into the UnitedHealthcare claims and was shocked to find the insurer had drawn up reimbursement checks payable to her practice and then deposited those checks into its own bank account, records shared with NBC News show. "They are trying to bankrupt our practice," Mazzola said. "Now, we're going to do brain surgery and instead of paying us, they're going to take the money themselves." Bryan Fisher, a spokesman for UnitedHealth Group, the conglomerate that owns the insurer, declined to comment on its actions related to Mazzola's practice, New Jersey Pediatric Neuroscience Institute. Her case sheds light on something few patients know about: the behind-the-scenes battles doctors say they must wage with insurers over reimbursements and the increasingly aggressive tactics taken by huge payers like UnitedHealthcare. Her experience also gives credence, antitrust experts say, to concerns that UnitedHealth Group's acquisitions of an array of health care operations in recent years have given it too much power over patients and the doctors treating them. "You've got physicians looking out for hundreds and thousands of families, and you've got this big corporate entity exerting as much financial power as it can, just because it can," said Josh Bengal, staff counsel at the Medical Society of New Jersey. "It's upsetting." The hack in February 2024 affected 190 million patients, making it the largest ever involving medical data. UnitedHealth Group ultimately paid a $22 million ransom to the cybercriminals. After the pause in reimbursements, many providers took out loans through Optum — over $9 billion was borrowed, according to company filings. Repayment terms on the loans were vague, with Mazzola's contract noting only that her practice would have to repay the loan within 30 business days of receiving notice from UnitedHealth Group. But Mazzola and other doctors said they were assured by the congressional testimony of Andrew Witty, UnitedHealth Group's former chief executive, who said in May 2024 that the company would seek repayment only when borrowers' businesses were back to normal. Even though Change Healthcare said it restarted claims processing about a month after the breach, doctors who spoke with NBC News said their operations continued to struggle long after, with some saying they are out millions as a result. Others were forced to close after being crippled by the loss of income. When Optum began demanding repayment of loans in January, it gave borrowers five business days, according to letters reviewed by NBC News. Those who didn't meet the demands could have their UnitedHealthcare reimbursements withheld as repayment, the letters say. Mazzola's practice had promised to submit $10,000 a month until her $535,000 loan was repaid. It was all she could afford, she told Optum in emails reviewed by NBC News. Mazzola said an Optum executive told her by phone that her repayments weren't enough. And in mid-February, UnitedHealthcare began intercepting reimbursements owed to Mazzola's practice "to repay amounts owed under your agreement with Change Healthcare Operations LLC," documents show. Upon further investigation, Mazzola learned the puzzling way UnitedHealthcare diverted the money — drawing up checks payable to Mazzola's practice and then depositing them into a UnitedHealthcare bank account, the documents show. "How can United Healthcare claw back money that we are due for surgeries and office visits?" Mazzola wrote to an Optum executive she had been dealing with. She received no response, but in April the company stopped seizing reimbursements from her practice after she complained to the American Medical Association. It waded into the fight on April 11, when Dr. James Madara, the AMA's chief executive, wrote to Roger Connor, the chief executive of Optum Insight, asking that the company stop its payment demands. "Physician practices are still suffering severe financial distress as a result of the cyberattack nearly 14 months after the breach was first discovered," Madara wrote. "We want Optum to honor its commitment to wait to recover repayment for any loans until the physician determines that it is the appropriate time, because the physicians have relied on Optum's statements." In a statement, Optum said it is working with providers "to identify flexible repayment plans based on the individual circumstances of providers and their practices." "We have also worked with UnitedHealthcare to ensure the claims it receives are reviewed in light of the challenges providers experienced, including waiving timely filing requirements for the plans under its control," it added. Multiple lawyers interviewed by NBC News reviewed the loan agreement Mazzola's practice signed and characterized it as a contract of adhesion — in which one party calls the shots and the other has little choice but to agree. The financial ruin Mazzola and other doctors faced because of the hack, an event caused by inadequate security at Change Healthcare, made the loans even more one-sided, some lawyers said. As a result, doctors may have legal recourse after the aggressive actions UnitedHealth Group took to extract loan repayments. The central question surrounding UnitedHealth Group's reimbursement actions is "whether they abused their use of this remedy by insisting on repayment before it was appropriate for them to do so given the damages that they caused," Daniel Schwarcz, a professor at the University of Minnesota law school, said in an email. Amid its clashes with doctors, UnitedHealth Group announced earnings of $9 billion from operations in the first quarter of 2025, a 15% jump from the same period last year. Revenue for the three months was $110 billion. Even after Change Healthcare restarted claims processing, doctors who spoke with NBC News said they were never reimbursed for many claims because the disruption meant they couldn't submit them within insurers' required time periods. The doctors also said their costs increased after the hack because they had to pay staff members to chase reimbursements. Mazzola, who estimates that her practice lost $1 million because of the hack, has asked Optum to reimburse her for costs her practice incurred as a result of the breach. But the terms Optum offered would have barred her from being able to sue it because of the hack. So she declined to accept it. "I really believed that Optum, who was orchestrating these loans, would give physicians and physician groups a reasonable amount of time to repay the loans with the understanding that this financial crisis almost bankrupted us," Mazzola said. "I mean literally, you're talking about $0 in your bank account, and you have 70 employees to pay." Doctors say they weren't the only ones hurt by the hack. Patients, too, were harmed when providers didn't have the reimbursement revenue needed to buy medicine, for example. "There were a lot of delays of patient care as a result of it," said Dr. Pruvi Parikh, an allergist and immunologist in New York City who is medical director of a practice with six locations in New York and 15 in New Jersey. Parikh's group borrowed $400,000 from Optum to survive the hack. By the end of 2024, it had repaid all but $102,000 of it, documents show. On Jan. 7, Optum threatened to withhold reimbursements to Parikh's practice if the rest of the loan wasn't repaid in days, an email shows. "Coming up with that amount of money in five business days is not possible for the majority of private practices," Parikh said in an interview. "Not only did they not give us time to get back on our feet, they were like, 'Pay it now.'" While the practice met Optum's demand, she estimated it is out $2 million because of the hack. In a statement, Change Healthcare said it started clawing back funding it had provided "more than one year post the event and with services restored." The company said it is reaching out to those "that have not been responsive to previous calls or email requests for more information." The main reason doctors like Parikh and Mazzola are in this crucible, antitrust experts and physicians say, is that UnitedHealth Group operates so many cogs in the nation's health care machinery. By acquiring an array of health care operations in recent years—including physician practices and pharmacy benefits management, technology, claims processing and financial services — UnitedHealth Group can exert market muscle over weaker participants like doctors and patients. Federal antitrust lawyers concerned about possible monopolistic activities have sued health care companies in recent years. In 2022, two years before the Change Healthcare hack, the Justice Department and the states of New York and Minnesota sued to stop UnitedHealth Group's acquisition of the claims processor, saying it would reduce competition in health care insurance markets. Because Change Healthcare dominates the claims clearinghouse business, the government argued, its purchase by UnitedHealth Group would give the conglomerate information about how rivals' insurance plans work, a competitive advantage. UnitedHealth disagreed, saying it had strong "firewalls" between units that would prevent sensitive data from being shared throughout the company. Optum, the subsidiary that now houses Change Healthcare, would protect external customers' data from being shared with UnitedHealthcare or its affiliates if the deal went through, the company said. That argument seemed to persuade the federal judge hearing the case in Washington, D.C., a Trump appointee. In his October 2022 decision greenlighting the $13 billion Change acquisition, U.S. District Judge Carl J. Nichols cited the company's data-sharing firewalls as weighing "strongly against the government's position." Now, doctors say UnitedHealthcare's diverting reimbursements to repay Optum loans shows the kind of data-sharing the government was concerned about. Hayden Rooke-Ley is senior fellow for health care at the American Economic Liberties Project, a nonprofit, nonpartisan organization that works to curb monopolies. He said UnitedHealth Group's seizure of doctors' reimbursements is an example of what happens when a company coordinates among its different subsidiaries for its own purposes. "These are the sorts of conflicts of interest we worry about when an insurance company also owns the payment pipes and a bank," Rooke-Ley said in an interview. Asked to respond to the criticism, Fisher of UnitedHealth Group declined. When it added Change Healthcare to its operations in late 2022, Optum said the combined companies would "benefit the entire health system, resulting in lower costs and a better experience for all stakeholders." Parikh, the New York City allergist and immunologist, begs to differ. "It was a complete disaster, and to this day it's not corrected," she said of the hack. "But there hasn't been any accountability to this goliath Optum."
NBC News
9 hours ago
- Business
- NBC News
Taking on Goliath: Brain surgeon's clash with UnitedHealthcare shows insurer's hardball tactics
U.S. news A massive hack of the insurance giant set off a chain of events that has left some doctors' practices on financial life support. June 20, 2025, 6:00 AM EDT By Gretchen Morgenson Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice in New Jersey that treats low-income children on Medicaid. Since 2008, she has cared for boys and girls with cerebral palsy, spina bifida and other neurological disorders. But now, her practice is in serious jeopardy, she says, because of recent moves by the insurance and health care giant UnitedHealth Group. The story begins in February 2024, when a unit of UnitedHealth experienced a massive hack. The unit, Change Healthcare, shuttered its systems and halted all reimbursements owed to hospitals and doctors like Mazzola. To help providers stay afloat, Optum, another UnitedHealth subsidiary that includes a bank, began offering " temporary," no-interest loans. Mazzola's practice was among those tapping into the program — it received $535,000, documents show. The practice began repaying the loans, but in January Optum demanded that it repay the money in full and within five business days. 'Our practice is doing the BEST we can,' Mazzola wrote in an email to Optum on Jan. 20. 'Please ask the loan collection people to STOP. We are already in repayment at the maximum possible amount monthly.' The situation soon got worse. In mid-February, she stopped receiving reimbursements from UnitedHealthcare. By April, her practice was out $78,000, her accountant's records show, and was struggling to make payroll. Mazzola dug into the UnitedHealthcare claims and was shocked to find the insurer had drawn up reimbursement checks payable to her practice and then deposited those checks into its own bank account, records shared with NBC News show. 'They are trying to bankrupt our practice,' Mazzola said. 'Now, we're going to do brain surgery and instead of paying us, they're going to take the money themselves.' Bryan Fisher, a spokesman for UnitedHealth Group, the conglomerate that owns the insurer, declined to comment on its actions related to Mazzola's practice, New Jersey Pediatric Neuroscience Institute. Her case sheds light on something few patients know about: the behind-the-scenes battles doctors say they must wage with insurers over reimbursements and the increasingly aggressive tactics taken by huge payers like UnitedHealthcare. Her experience also gives credence, antitrust experts say, to concerns that UnitedHealth Group's acquisitions of an array of health care operations in recent years have given it too much power over patients and the doctors treating them. 'You've got physicians looking out for hundreds and thousands of families, and you've got this big corporate entity exerting as much financial power as it can, just because it can,' said Josh Bengal, staff counsel at the Medical Society of New Jersey. 'It's upsetting.' '$0 in your bank account' The hack in February 2024 affected 190 million patients, making it the largest ever involving medical data. UnitedHealth Group ultimately paid a $22 million ransom to the cybercriminals. After the pause in reimbursements, many providers took out loans through Optum — over $9 billion was borrowed, according to company filings. Repayment terms on the loans were vague, with Mazzola's contract noting only that her practice would have to repay the loan within 30 business days of receiving notice from UnitedHealth Group. But Mazzola and other doctors said they were assured by the congressional testimony of Andrew Witty, UnitedHealth Group's former chief executive, who said in May 2024 that the company would seek repayment only when borrowers' businesses were back to normal. Even though Change Healthcare said it restarted claims processing about a month after the breach, doctors who spoke with NBC News said their operations continued to struggle long after, with some saying they are out millions as a result. Others were forced to close after being crippled by the loss of income. When Optum began demanding repayment of loans in January, it gave borrowers five business days, according to letters reviewed by NBC News. Those who didn't meet the demands could have their UnitedHealthcare reimbursements withheld as repayment, the letters say. Mazzola's practice had promised to submit $10,000 a month until her $535,000 loan was repaid. It was all she could afford, she told Optum in emails reviewed by NBC News. Mazzola said an Optum executive told her by phone that her repayments weren't enough. And in mid-February, UnitedHealthcare began intercepting reimbursements owed to Mazzola's practice 'to repay amounts owed under your agreement with Change Healthcare Operations LLC,' documents show. Upon further investigation, Mazzola learned the puzzling way UnitedHealthcare diverted the money — drawing up checks payable to Mazzola's practice and then depositing them into a UnitedHealthcare bank account, the documents show. 'How can United Healthcare claw back money that we are due for surgeries and office visits?' Mazzola wrote to an Optum executive she had been dealing with. She received no response, but in April the company stopped seizing reimbursements from her practice after she complained to the American Medical Association. It waded into the fight on April 11, when Dr. James Madara, the AMA's chief executive, wrote to Roger Connor, the chief executive of Optum Insight, asking that the company stop its payment demands. 'Physician practices are still suffering severe financial distress as a result of the cyberattack nearly 14 months after the breach was first discovered,' Madara wrote. 'We want Optum to honor its commitment to wait to recover repayment for any loans until the physician determines that it is the appropriate time, because the physicians have relied on Optum's statements.' In a statement, Optum said it is working with providers 'to identify flexible repayment plans based on the individual circumstances of providers and their practices.' 'We have also worked with UnitedHealthcare to ensure the claims it receives are reviewed in light of the challenges providers experienced, including waiving timely filing requirements for the plans under its control,' it added. Multiple lawyers interviewed by NBC News reviewed the loan agreement Mazzola's practice signed and characterized it as a contract of adhesion — in which one party calls the shots and the other has little choice but to agree. The financial ruin Mazzola and other doctors faced because of the hack, an event caused by inadequate security at Change Healthcare, made the loans even more one-sided, some lawyers said. As a result, doctors may have legal recourse after the aggressive actions UnitedHealth Group took to extract loan repayments. The central question surrounding UnitedHealth Group's reimbursement actions is 'whether they abused their use of this remedy by insisting on repayment before it was appropriate for them to do so given the damages that they caused,' Daniel Schwarcz, a professor at the University of Minnesota law school, said in an email. Amid its clashes with doctors, UnitedHealth Group announced earnings of $9 billion from operations in the first quarter of 2025, a 15% jump from the same period last year. Revenue for the three months was $110 billion. Even after Change Healthcare restarted claims processing, doctors who spoke with NBC News said they were never reimbursed for many claims because the disruption meant they couldn't submit them within insurers' required time periods. The doctors also said their costs increased after the hack because they had to pay staff members to chase reimbursements. Mazzola, who estimates that her practice lost $1 million because of the hack, has asked Optum to reimburse her for costs her practice incurred as a result of the breach. But the terms Optum offered would have barred her from being able to sue it because of the hack. So she declined to accept it. 'I really believed that Optum, who was orchestrating these loans, would give physicians and physician groups a reasonable amount of time to repay the loans with the understanding that this financial crisis almost bankrupted us,' Mazzola said. 'I mean literally, you're talking about $0 in your bank account, and you have 70 employees to pay.' Delays of patient care Doctors say they weren't the only ones hurt by the hack. Patients, too, were harmed when providers didn't have the reimbursement revenue needed to buy medicine, for example. 'There were a lot of delays of patient care as a result of it,' said Dr. Pruvi Parikh, an allergist and immunologist in New York City who is medical director of a practice with six locations in New York and 15 in New Jersey. Parikh's group borrowed $400,000 from Optum to survive the hack. By the end of 2024, it had repaid all but $102,000 of it, documents show. On Jan. 7, Optum threatened to withhold reimbursements to Parikh's practice if the rest of the loan wasn't repaid in days, an email shows. 'Coming up with that amount of money in five business days is not possible for the majority of private practices,' Parikh said in an interview. 'Not only did they not give us time to get back on our feet, they were like, 'Pay it now.'' While the practice met Optum's demand, she estimated it is out $2 million because of the hack. In a statement, Change Healthcare said it started clawing back funding it had provided 'more than one year post the event and with services restored.' The company said it is reaching out to those 'that have not been responsive to previous calls or email requests for more information.' The main reason doctors like Parikh and Mazzola are in this crucible, antitrust experts and physicians say, is that UnitedHealth Group operates so many cogs in the nation's health care machinery. By acquiring an array of health care operations in recent years—including physician practices and pharmacy benefits management, technology, claims processing and financial services — UnitedHealth Group can exert market muscle over weaker participants like doctors and patients. Federal antitrust lawyers concerned about possible monopolistic activities have sued health care companies in recent years. In 2022, two years before the Change Healthcare hack, the Justice Department and the states of New York and Minnesota sued to stop UnitedHealth Group's acquisition of the claims processor, saying it would reduce competition in health care insurance markets. Because Change Healthcare dominates the claims clearinghouse business, the government argued, its purchase by UnitedHealth Group would give the conglomerate information about how rivals' insurance plans work, a competitive advantage. UnitedHealth disagreed, saying it had strong 'firewalls' between units that would prevent sensitive data from being shared throughout the company. Optum, the subsidiary that now houses Change Healthcare, would protect external customers' data from being shared with UnitedHealthcare or its affiliates if the deal went through, the company said. That argument seemed to persuade the federal judge hearing the case in Washington, D.C., a Trump appointee. In his October 2022 decision greenlighting the $13 billion Change acquisition, U.S. District Judge Carl J. Nichols cited the company's data-sharing firewalls as weighing 'strongly against the government's position.' Now, doctors say UnitedHealthcare's diverting reimbursements to repay Optum loans shows the kind of data-sharing the government was concerned about. Hayden Rooke-Ley is senior fellow for health care at the American Economic Liberties Project, a nonprofit, nonpartisan organization that works to curb monopolies. He said UnitedHealth Group's seizure of doctors' reimbursements is an example of what happens when a company coordinates among its different subsidiaries for its own purposes. 'These are the sorts of conflicts of interest we worry about when an insurance company also owns the payment pipes and a bank,' Rooke-Ley said in an interview. Asked to respond to the criticism, Fisher of UnitedHealth Group declined. When it added Change Healthcare to its operations in late 2022, Optum said the combined companies would 'benefit the entire health system, resulting in lower costs and a better experience for all stakeholders.' Parikh, the New York City allergist and immunologist, begs to differ. 'It was a complete disaster, and to this day it's not corrected,' she said of the hack. 'But there hasn't been any accountability to this goliath Optum.' Gretchen Morgenson Gretchen Morgenson is the senior financial reporter for the NBC News Investigative Unit. A former stockbroker, she won the Pulitzer Prize in 2002 for her "trenchant and incisive" reporting on Wall Street.
Yahoo
12 hours ago
- Business
- Yahoo
UnitedHealth's Rebound: Hidden Strength or Hiding Weakness?
Recently, UnitedHealth Group (UNH, Financial) has been the subject of many headlines because of DOJ probes, kickback accusations in nursing homes, and a shocking departure of its CEO. In addition, the value of its shares has dropped by almost 50%. Yet, underneath the news, the business is still strong. Health insurance remains important and strong throughout economic downturns and doesn't react to changes in global trade. In the aftermath, a clear development can be noticed as Stephen Hemsley was appointed CEO again and bought a large amount of stock which fueled a quick increase in share prices. Warning! GuruFocus has detected 4 Warning Sign with UNH. This is real conviction. UnitedHealth is focusing more on Medicaid-managed care, widening value-based care with Optum, and looking into growing its business in dual-eligible and long-term care. The company's financials confirm the trend since earnings have quadrupled in ten years, cash flow is strong, and insiders are buying in. In short, UnitedHealth is using the uncertainty to its advantage. Long-term investors may find the current price as an attractive chance to enter a company that has shown lasting and solid growth. UnitedHealth Group is the biggest health insurer in the United States and ranks highly internationally in healthcare. Its two key segments, UnitedHealthcare and Optum, give people health benefits, pharmacy services, data analysis, and healthcare. More than 150 million people are helped by this company, which is continuing to expand by combining operations and offering value-based care. The company provides insurance through commercial, Medicare, and Medicaid markets, and Optum sparks new ideas in care coordination and pharmaceutical services. UnitedHealth is smartly diversified. The company is doing well due to managed care growth, making money from healthcare improvements, and strategically serving top segments thanks to Optum doing the main work. Medicaid managed care expansion capturing state-level shifts: The move of Medicaid recipients from fee-for-service to managed care can bring huge benefits to UnitedHealth. According to industry statistics, UNH and four other large insurers cover over 50% of people in Medicaid-managed care across the nation. So, when several hundred thousand to millions switch plans, it has a huge effect on the company's finances. Since monthly premiums for complex patients in these states are $600$800, New York, Pennsylvania, and Michigan could add hundreds of millions of dollars to their annual premium earnings. Because of its connections with states, UNH is in a good position to win a major share of this revenue. Value-based care & optum scale turning outcomes into profit: Optum, which drives UNH's value-based approach, recorded $253 billion in revenue in 2024, which was 12% higher than the previous year, and $16.7 billion in operating income. Currently, Optum Health works with close to 4.7 million people in value-based contracts and plans to add another 650k in 2025. Focus on patient care and cost savings are the main aims of these models, and UNH supports this. When Optum grows its care coordination and home services, shared-savings revenue plays a bigger role, already bringing in hundreds of millions and capable of much more. High-Value segments target the dual-eligible and long-term care markets: Instead of raising its volume, UNH is focusing on high-paying customer groups, such as those with both Medicare and Medicaid and patients needing long-term care. Dual-eligibles may receive $2,500 monthly, which means each person will get $30,000 annually. Currently, UNH serves about 500k people, but if it could capture just 2 million of the national enrollments, it could earn $45 billion in annual premiums. Vertical integration with optum: Thanks to Optum, UNH has all its services combined, including pharmacy (over 1.62 billion scripts were handled by OptumRx in 2024), care delivery, data analysis, and provider management. Because of this integration, UNH is ahead in long-term care, managing care effectively, reducing expenses, and boosting results, which other organizations don't have. Overall, UnitedHealth is a leader that is making steady earnings now and is prepared to capture the future of healthcare and population wellness. Now, let's investigate the financial side of UnitedHealth Group. The company had good first-quarter earnings, but it sent a cautious message for the coming months. UnitedHealth Group's quarterly revenue of $109.6 billion was $10 billion higher than the same period last year, showing how much both UnitedHealthcare and Optum are growing. While adjusted EPS of $7.20 surpassed $6.91 from the earlier period, the company adjusted its full-year forecast down to expect adjusted EPS of $26.00 to $26.50. So, what leads to this change of tone? While UnitedHealthcare welcomed 780,000 new members, increased use of health services in Medicare Advantage by its customers caused the company's medical costs to increase above expectations. Because more people needed outpatient and physician care, the medical care ratio rose to 84.8%. For healthcare delivery, this is not necessarily an issue, yet it can still hurt business if prices fall short. Meanwhile, Optum Health experienced challenges with a more diverse member group and reduced payments due to less involvement among members in 2024. Even so, Optum achieved a $63.9 billion revenue thanks to its Rx division, which filled 408 million adjusted scripts. UNH is also operating efficiently, with its operating cost ratio now 12.4%, free cash flow at $5.5 billion, and a high 26.8% return on equity. The company also gave $5 billion back to its shareholders. All in all, UNH's basics are solid, but it has to deal with some short-term problems first. UnitedHealth Group has consistently improved its earnings over the years. In the year 2015, diluted earnings per share was only $6.01. Looking at the trailing twelve months, the number has reached $23.88. Over the past decade, the amount has almost quadrupled. It is even more impressive that the growth has been steady over the years. For many years, UnitedHealth kept increasing its profits, demonstrating the power of its varied businesses and strict management. The only major drop in EPS happened in 2024, with the figure reaching $15.51. Although this was an unusual dip in the company's history, it is on track for a solid recovery in 2025, and first-quarter adjusted EPS was $7.20. Looking into the future, analysts believe the trend will not stop. Even though 2025 is, in some ways, a year of recovery with a projected EPS of $22.59, the company's growth kicks in afterward. By 2026, analysts predict EPS will increase to $26.40, and then keep growing at double-digit rates, aiming for $45.83 by 2030. Source: Author generated based on historical data All in all, despite some occasional setbacks, UnitedHealth's future growth is steady, so patient investors are still in a position to be rewarded. The increase in EPS matches the upward trend in revenue per share. It highlights the company's steady growth and increased success. In the year 2015, the company's revenue per share was $162.47. Now, that figure is $443.16 TTM. That's a 170% jump in ten years, which clearly shows the company is making better use of its growth to help shareholders. What's most promising is that this growth keeps happening consistently. Revenue per share has increased year after year and stayed strong through different economic conditions and impacts on the industry. It is a result of the company attracting more members and expanding its main businesses, UnitedHealthcare and Optum. Once more, this trend keeps happening in the future. Revenue forecasts keep going up from $449.81 billion in 2025 to more than $591 billion by 2030. Minor changes in growth do not stop the company from expanding and creating more value for its shareholders. Source: Author generated based on historical data UnitedHealth Group's free cash flow per share is a reliable sign of how well the company is financially and operationally. The amount of free cash flow per share in 2015 was $8.46. Afterward, the company increased this number, reaching $26.82 for the TTM, which is more than three times higher than its value a decade back. What stands out about this growth is that it follows closely in line with the company's earnings trajectory. Therefore, we see that UnitedHealth's profits are being turned into cash that can be used to strengthen the business, cut debt, or be given back to its shareholders. Being that efficient is not common in an industry that relies heavily on capital like healthcare. UnitedHealth Group gives investors a good dividend since the dividend yield is 2.92% and the payout ratio is only 30%, which suggests that dividends could increase in the future. It's worth noting that over the past 5 years, the company has seen a 14.6% growth in its dividend, which tops inflation and profits long-term investors. Through ten years of constant raises, the yield on cost increases to 15.38%. Although UNH is offering a high yield now, low buybacks mean most capital is shared through dividends. UnitedHealth Group looks deeply undervalued right now. According to GuruFocus, the stock is trading about half its worth, as the fair value is $633.16 but it is currently trading at $303.22. There is a massive disconnect here, and it's very unusual for a company as stable as UNH to deviate so much from its fair value estimate. Valuation multiples are also telling the same story. The forward P/E of this stock is 13.42, which is much lower than the average of 17.66, giving a discount of 23.98%. The company's forward EV/EBITDA of 9.61 is better than the sector's ratio of 11.79. On a price-to-sales ratio, UNH is trading at 0.61 times its projected sales, while the healthcare industry is pricing in at 3.43xa discount of 82%. All in all, UNH gives you both quality and value. Almost all of the valuation measures suggest that the company is undervalued in terms of its earnings, sales, and cash flow. Even though the stock is built on solid foundations and pays out more in dividends each year, it still trades at a lower price than its competitors. As a result, long-term investors can take advantage of acquiring a leader in healthcare at a much lower price than its actual value. When measured against companies like Humana (HUM, Financial) and HealthEquity (HQY, Financial), UnitedHealth Group is still a good buy. Because its forward P/E is lower than HUM's 14.1 times and much lower than HQY's 30 times, it attracts those who want to invest for growth as well as value. Considering price-to-sales, UNH trades at 0.68 times, making it more valuable than HQY's 7.8 while being slightly higher than HUM's very low 0.23. On the EV/EBITDA ratio, UNH stands at 9.6x forward, quite similar to HUM's 9.2x and much less than HQY's 19.2x. All in all, UNH is well-balanced by giving investors scale, profits, dividend growth, and a reasonably attractive price. HUM also does well in various areas, especially when it comes to managing expenses and the way the company works. But in the long run, investors admire UNH for its consistent results and potential to increase. Source: Author generated based on data Going forward, I feel UnitedHealth Group (NYSE:UNH) is well-positioned to achieve a price target of $395$410 in the next year and possibly surpass $525$550 by 2027. Despite the stock's recent volatility, the numbers, the company's health, and the outlook seem to fit together nicely. Let's begin our discussion with the short term. Despite many years of increasing earnings and a high rate of cash conversion, UNH is only valued at 13.4 times its future earnings when the stock is trading at $303. Healthcare companies, on the other hand, have a forward P/E of about 17.6, and UNH has generally had a forward P/E between 18x and 20x during calm times. If UNH is valued at just 17 times the expected FY2025 EPS of $22.59, the price would come to $384. At 18x, If stability comes back and the new leaders reassure everyone, the stock could increase to $406. The story gets even better as you look further into the future. Analysts are predicting that EPS will rise to $45.83 by 2030, meaning it will be about double the current earnings in just five years. Multiply the earnings by 15, and the share price comes out to $687. But, let's narrow our focus to conservatism, and for 2027, the predicted EPS is about $34.50. At this multiple of 15x, the price comes out to $517if the market recovers, shares could climb to $550 or more due to the 16x or 17x rating. If the DOJ investigation ends well and Hemsley's efforts to cut costs are successful, the company should do well over the next few quarters. We are not just discussing theory here. Since 2015, UNH's free cash flow per share has more than tripled, its revenue per share has nearly tripled too, and it still has some of the top dividend growth rates in healthcare. Such consistency, size, and under-valuation are hard to find in one company. Let's look at how Wall Street views this area. Looking at the chart, analysts foresee that the price of Apple shares might rise by 26.2% to $382.80 in the next 12 months. It is estimated that the cost can fall anywhere from $270 to $677. To conclude, although there may be short-term ups and downs, it looks like disciplined, patient investors will find more favorable long-term conditions. When Andrew Witty suddenly left his CEO post in May because of profit problems and dropped 2025 guidance, UNH shares fell over 12% to their lowest point in five years and wiped out more than $250 billion in market value. As a consequence, the board brought back former CEO Stephen Hemsley (who headed the company from 2006 to 2017). Within only a few days, Hemsley made a big step by buying nearly 86,700 shares worth about $25 million for $288.60 per share. Hemsley, together with the CFO and several directors, voted to keep the company's value high, and shares rose by about 8% the following trading day. What does it imply? It is clear that the management views the falling share price of UNH as a good time to purchase. The fact that Hemsley has invested his money shows how much he believes in the company after all it has achieved. Yet, this is not a case of blind faith: the company is dealing with an ongoing investigation, higher medical costs in Medicare Advantage, and a cyberattack it suffered recently. From a strategic point of view, all this buying in UNH suggests that the company's leaders believe the worst has passed and risks for the stock are low. The guru trading chart has an interesting narrative. Although UnitedHealth's stock has gone down recently, gurus have been buying it more frequently. Many green bars are appearing, both early in 2024 and again later in 2025, showing that some informed investors are looking at the dip as an opportunity to buy instead of a warning sign. This trend can be seen in the investor's stock portfolio. Vanguard is still the biggest shareholder, but it slightly reduced its holdings. I'm also paying attention to Ken Fisher (Trades, Portfolio) , who bought much more, a solid 52%, and Jeremy Grantham (Trades, Portfolio) , who increased his holding by over 7%. Though there is selling and shares are reduced as well, institutions tend to be cautiously upbeat. Even though UnitedHealth's future looks bright, investors should still pay attention to the risks in the near term. The DOJ is currently investigating the business for possible Medicare Advantage fraud, such as upcoding and billing errors, which is a very serious matter that could result in being fined or charged in court. At the same moment, Washington is paying more attention to supervision. Should reforms reduce the inflation of risk scores or Medicare allowance for nurse practitioners, it could affect the profitability of Medicare Advantage. Q1 faced some issues because the higher use of medical services caused the medical loss ratio to increase to around 85%, and Optum is still learning to handle CMS's updated risk model. Because of these pressures, there could be more budget reductions for guidance. However, the bad news appears to be mostly factored into share prices. For careful investors who believe the company will survive, this could present an opportunity to buy long-term. The headlines can be very tempting, but stepping back, it appears that UnitedHealth is still a powerhouse lurking in plain sight. It is the same old stuff but with a different sentiment. The long-term story is still in place with the reinstatement of Stephen Hemsley, a recent insider purchase, and a long history of expertise in Medicaid-managed care and the Optum platform in value-based care. Most of that bad news, including the increases in care costs, and regulatory noise, appears to be reflected in price. Sentiment can change at any minute as long as we hear a resolution to the DOJ investigation, a slowdown in the trend of rising Medicare costs, or upbeat guidance in coming quarters. Any of those may be the spark. In the meantime, the stock is currently trading at one of the most attractive valuations it has seen in years, and the set-up is of the sort long-term investors tend to reflect back on with gratitude. If you are waiting to have a clear picture, you may miss the opportunity. However, to the patient and longer-term investors, this may be one of those times when interceding in soreness results in actual payoff. In other words, this just might be a smart time to lean in and buy the stock. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
12 hours ago
- Business
- Yahoo
UnitedHealth's Rebound: Hidden Strength or Hiding Weakness?
Recently, UnitedHealth Group (UNH, Financial) has been the subject of many headlines because of DOJ probes, kickback accusations in nursing homes, and a shocking departure of its CEO. In addition, the value of its shares has dropped by almost 50%. Yet, underneath the news, the business is still strong. Health insurance remains important and strong throughout economic downturns and doesn't react to changes in global trade. In the aftermath, a clear development can be noticed as Stephen Hemsley was appointed CEO again and bought a large amount of stock which fueled a quick increase in share prices. Warning! GuruFocus has detected 4 Warning Sign with UNH. This is real conviction. UnitedHealth is focusing more on Medicaid-managed care, widening value-based care with Optum, and looking into growing its business in dual-eligible and long-term care. The company's financials confirm the trend since earnings have quadrupled in ten years, cash flow is strong, and insiders are buying in. In short, UnitedHealth is using the uncertainty to its advantage. Long-term investors may find the current price as an attractive chance to enter a company that has shown lasting and solid growth. UnitedHealth Group is the biggest health insurer in the United States and ranks highly internationally in healthcare. Its two key segments, UnitedHealthcare and Optum, give people health benefits, pharmacy services, data analysis, and healthcare. More than 150 million people are helped by this company, which is continuing to expand by combining operations and offering value-based care. The company provides insurance through commercial, Medicare, and Medicaid markets, and Optum sparks new ideas in care coordination and pharmaceutical services. UnitedHealth is smartly diversified. The company is doing well due to managed care growth, making money from healthcare improvements, and strategically serving top segments thanks to Optum doing the main work. Medicaid managed care expansion capturing state-level shifts: The move of Medicaid recipients from fee-for-service to managed care can bring huge benefits to UnitedHealth. According to industry statistics, UNH and four other large insurers cover over 50% of people in Medicaid-managed care across the nation. So, when several hundred thousand to millions switch plans, it has a huge effect on the company's finances. Since monthly premiums for complex patients in these states are $600$800, New York, Pennsylvania, and Michigan could add hundreds of millions of dollars to their annual premium earnings. Because of its connections with states, UNH is in a good position to win a major share of this revenue. Value-based care & optum scale turning outcomes into profit: Optum, which drives UNH's value-based approach, recorded $253 billion in revenue in 2024, which was 12% higher than the previous year, and $16.7 billion in operating income. Currently, Optum Health works with close to 4.7 million people in value-based contracts and plans to add another 650k in 2025. Focus on patient care and cost savings are the main aims of these models, and UNH supports this. When Optum grows its care coordination and home services, shared-savings revenue plays a bigger role, already bringing in hundreds of millions and capable of much more. High-Value segments target the dual-eligible and long-term care markets: Instead of raising its volume, UNH is focusing on high-paying customer groups, such as those with both Medicare and Medicaid and patients needing long-term care. Dual-eligibles may receive $2,500 monthly, which means each person will get $30,000 annually. Currently, UNH serves about 500k people, but if it could capture just 2 million of the national enrollments, it could earn $45 billion in annual premiums. Vertical integration with optum: Thanks to Optum, UNH has all its services combined, including pharmacy (over 1.62 billion scripts were handled by OptumRx in 2024), care delivery, data analysis, and provider management. Because of this integration, UNH is ahead in long-term care, managing care effectively, reducing expenses, and boosting results, which other organizations don't have. Overall, UnitedHealth is a leader that is making steady earnings now and is prepared to capture the future of healthcare and population wellness. Now, let's investigate the financial side of UnitedHealth Group. The company had good first-quarter earnings, but it sent a cautious message for the coming months. UnitedHealth Group's quarterly revenue of $109.6 billion was $10 billion higher than the same period last year, showing how much both UnitedHealthcare and Optum are growing. While adjusted EPS of $7.20 surpassed $6.91 from the earlier period, the company adjusted its full-year forecast down to expect adjusted EPS of $26.00 to $26.50. So, what leads to this change of tone? While UnitedHealthcare welcomed 780,000 new members, increased use of health services in Medicare Advantage by its customers caused the company's medical costs to increase above expectations. Because more people needed outpatient and physician care, the medical care ratio rose to 84.8%. For healthcare delivery, this is not necessarily an issue, yet it can still hurt business if prices fall short. Meanwhile, Optum Health experienced challenges with a more diverse member group and reduced payments due to less involvement among members in 2024. Even so, Optum achieved a $63.9 billion revenue thanks to its Rx division, which filled 408 million adjusted scripts. UNH is also operating efficiently, with its operating cost ratio now 12.4%, free cash flow at $5.5 billion, and a high 26.8% return on equity. The company also gave $5 billion back to its shareholders. All in all, UNH's basics are solid, but it has to deal with some short-term problems first. UnitedHealth Group has consistently improved its earnings over the years. In the year 2015, diluted earnings per share was only $6.01. Looking at the trailing twelve months, the number has reached $23.88. Over the past decade, the amount has almost quadrupled. It is even more impressive that the growth has been steady over the years. For many years, UnitedHealth kept increasing its profits, demonstrating the power of its varied businesses and strict management. The only major drop in EPS happened in 2024, with the figure reaching $15.51. Although this was an unusual dip in the company's history, it is on track for a solid recovery in 2025, and first-quarter adjusted EPS was $7.20. Looking into the future, analysts believe the trend will not stop. Even though 2025 is, in some ways, a year of recovery with a projected EPS of $22.59, the company's growth kicks in afterward. By 2026, analysts predict EPS will increase to $26.40, and then keep growing at double-digit rates, aiming for $45.83 by 2030. Source: Author generated based on historical data All in all, despite some occasional setbacks, UnitedHealth's future growth is steady, so patient investors are still in a position to be rewarded. The increase in EPS matches the upward trend in revenue per share. It highlights the company's steady growth and increased success. In the year 2015, the company's revenue per share was $162.47. Now, that figure is $443.16 TTM. That's a 170% jump in ten years, which clearly shows the company is making better use of its growth to help shareholders. What's most promising is that this growth keeps happening consistently. Revenue per share has increased year after year and stayed strong through different economic conditions and impacts on the industry. It is a result of the company attracting more members and expanding its main businesses, UnitedHealthcare and Optum. Once more, this trend keeps happening in the future. Revenue forecasts keep going up from $449.81 billion in 2025 to more than $591 billion by 2030. Minor changes in growth do not stop the company from expanding and creating more value for its shareholders. Source: Author generated based on historical data UnitedHealth Group's free cash flow per share is a reliable sign of how well the company is financially and operationally. The amount of free cash flow per share in 2015 was $8.46. Afterward, the company increased this number, reaching $26.82 for the TTM, which is more than three times higher than its value a decade back. What stands out about this growth is that it follows closely in line with the company's earnings trajectory. Therefore, we see that UnitedHealth's profits are being turned into cash that can be used to strengthen the business, cut debt, or be given back to its shareholders. Being that efficient is not common in an industry that relies heavily on capital like healthcare. UnitedHealth Group gives investors a good dividend since the dividend yield is 2.92% and the payout ratio is only 30%, which suggests that dividends could increase in the future. It's worth noting that over the past 5 years, the company has seen a 14.6% growth in its dividend, which tops inflation and profits long-term investors. Through ten years of constant raises, the yield on cost increases to 15.38%. Although UNH is offering a high yield now, low buybacks mean most capital is shared through dividends. UnitedHealth Group looks deeply undervalued right now. According to GuruFocus, the stock is trading about half its worth, as the fair value is $633.16 but it is currently trading at $303.22. There is a massive disconnect here, and it's very unusual for a company as stable as UNH to deviate so much from its fair value estimate. Valuation multiples are also telling the same story. The forward P/E of this stock is 13.42, which is much lower than the average of 17.66, giving a discount of 23.98%. The company's forward EV/EBITDA of 9.61 is better than the sector's ratio of 11.79. On a price-to-sales ratio, UNH is trading at 0.61 times its projected sales, while the healthcare industry is pricing in at 3.43xa discount of 82%. All in all, UNH gives you both quality and value. Almost all of the valuation measures suggest that the company is undervalued in terms of its earnings, sales, and cash flow. Even though the stock is built on solid foundations and pays out more in dividends each year, it still trades at a lower price than its competitors. As a result, long-term investors can take advantage of acquiring a leader in healthcare at a much lower price than its actual value. When measured against companies like Humana (HUM, Financial) and HealthEquity (HQY, Financial), UnitedHealth Group is still a good buy. Because its forward P/E is lower than HUM's 14.1 times and much lower than HQY's 30 times, it attracts those who want to invest for growth as well as value. Considering price-to-sales, UNH trades at 0.68 times, making it more valuable than HQY's 7.8 while being slightly higher than HUM's very low 0.23. On the EV/EBITDA ratio, UNH stands at 9.6x forward, quite similar to HUM's 9.2x and much less than HQY's 19.2x. All in all, UNH is well-balanced by giving investors scale, profits, dividend growth, and a reasonably attractive price. HUM also does well in various areas, especially when it comes to managing expenses and the way the company works. But in the long run, investors admire UNH for its consistent results and potential to increase. Source: Author generated based on data Going forward, I feel UnitedHealth Group (NYSE:UNH) is well-positioned to achieve a price target of $395$410 in the next year and possibly surpass $525$550 by 2027. Despite the stock's recent volatility, the numbers, the company's health, and the outlook seem to fit together nicely. Let's begin our discussion with the short term. Despite many years of increasing earnings and a high rate of cash conversion, UNH is only valued at 13.4 times its future earnings when the stock is trading at $303. Healthcare companies, on the other hand, have a forward P/E of about 17.6, and UNH has generally had a forward P/E between 18x and 20x during calm times. If UNH is valued at just 17 times the expected FY2025 EPS of $22.59, the price would come to $384. At 18x, If stability comes back and the new leaders reassure everyone, the stock could increase to $406. The story gets even better as you look further into the future. Analysts are predicting that EPS will rise to $45.83 by 2030, meaning it will be about double the current earnings in just five years. Multiply the earnings by 15, and the share price comes out to $687. But, let's narrow our focus to conservatism, and for 2027, the predicted EPS is about $34.50. At this multiple of 15x, the price comes out to $517if the market recovers, shares could climb to $550 or more due to the 16x or 17x rating. If the DOJ investigation ends well and Hemsley's efforts to cut costs are successful, the company should do well over the next few quarters. We are not just discussing theory here. Since 2015, UNH's free cash flow per share has more than tripled, its revenue per share has nearly tripled too, and it still has some of the top dividend growth rates in healthcare. Such consistency, size, and under-valuation are hard to find in one company. Let's look at how Wall Street views this area. Looking at the chart, analysts foresee that the price of Apple shares might rise by 26.2% to $382.80 in the next 12 months. It is estimated that the cost can fall anywhere from $270 to $677. To conclude, although there may be short-term ups and downs, it looks like disciplined, patient investors will find more favorable long-term conditions. When Andrew Witty suddenly left his CEO post in May because of profit problems and dropped 2025 guidance, UNH shares fell over 12% to their lowest point in five years and wiped out more than $250 billion in market value. As a consequence, the board brought back former CEO Stephen Hemsley (who headed the company from 2006 to 2017). Within only a few days, Hemsley made a big step by buying nearly 86,700 shares worth about $25 million for $288.60 per share. Hemsley, together with the CFO and several directors, voted to keep the company's value high, and shares rose by about 8% the following trading day. What does it imply? It is clear that the management views the falling share price of UNH as a good time to purchase. The fact that Hemsley has invested his money shows how much he believes in the company after all it has achieved. Yet, this is not a case of blind faith: the company is dealing with an ongoing investigation, higher medical costs in Medicare Advantage, and a cyberattack it suffered recently. From a strategic point of view, all this buying in UNH suggests that the company's leaders believe the worst has passed and risks for the stock are low. The guru trading chart has an interesting narrative. Although UnitedHealth's stock has gone down recently, gurus have been buying it more frequently. Many green bars are appearing, both early in 2024 and again later in 2025, showing that some informed investors are looking at the dip as an opportunity to buy instead of a warning sign. This trend can be seen in the investor's stock portfolio. Vanguard is still the biggest shareholder, but it slightly reduced its holdings. I'm also paying attention to Ken Fisher (Trades, Portfolio) , who bought much more, a solid 52%, and Jeremy Grantham (Trades, Portfolio) , who increased his holding by over 7%. Though there is selling and shares are reduced as well, institutions tend to be cautiously upbeat. Even though UnitedHealth's future looks bright, investors should still pay attention to the risks in the near term. The DOJ is currently investigating the business for possible Medicare Advantage fraud, such as upcoding and billing errors, which is a very serious matter that could result in being fined or charged in court. At the same moment, Washington is paying more attention to supervision. Should reforms reduce the inflation of risk scores or Medicare allowance for nurse practitioners, it could affect the profitability of Medicare Advantage. Q1 faced some issues because the higher use of medical services caused the medical loss ratio to increase to around 85%, and Optum is still learning to handle CMS's updated risk model. Because of these pressures, there could be more budget reductions for guidance. However, the bad news appears to be mostly factored into share prices. For careful investors who believe the company will survive, this could present an opportunity to buy long-term. The headlines can be very tempting, but stepping back, it appears that UnitedHealth is still a powerhouse lurking in plain sight. It is the same old stuff but with a different sentiment. The long-term story is still in place with the reinstatement of Stephen Hemsley, a recent insider purchase, and a long history of expertise in Medicaid-managed care and the Optum platform in value-based care. Most of that bad news, including the increases in care costs, and regulatory noise, appears to be reflected in price. Sentiment can change at any minute as long as we hear a resolution to the DOJ investigation, a slowdown in the trend of rising Medicare costs, or upbeat guidance in coming quarters. Any of those may be the spark. In the meantime, the stock is currently trading at one of the most attractive valuations it has seen in years, and the set-up is of the sort long-term investors tend to reflect back on with gratitude. If you are waiting to have a clear picture, you may miss the opportunity. However, to the patient and longer-term investors, this may be one of those times when interceding in soreness results in actual payoff. In other words, this just might be a smart time to lean in and buy the stock. This article first appeared on GuruFocus. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
a day ago
- Business
- Yahoo
UnitedHealth Group Looks to Exit Latin America. Is This a Good Move for Investors, or a Sign of More Problems Ahead?
UnitedHealth Group recently announced plans to exit its Latin American operations. It acquired Banmedica in 2018 as a way to enhance its growth opportunities. The move hasn't paid off, however, with UnitedHealth incurring significant losses on that business since then. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) is in the headlines again, this time, it's to announce that it is exiting Latin America. The announcement is just the latest in a series of news events in what has been a tumultuous year for the once-safe healthcare giant, whose shares are down a staggering 38% year to date as of June 13. There's been a flurry of bad news surrounding this business, including a change in its CEO last month. Does the company exiting Latin America signal more challenges ahead for the business, and could that affect its long-term growth? Here's what you need to know about this latest development and whether or not you should consider investing in the healthcare stock today. In 2018, UnitedHealth acquired Chilean healthcare company Banmedica in a deal worth $2.8 billion. The deal, however, hasn't paid off for the big health insurer as it has incurred losses totaling more than $8 billion on its Latin American operations since the takeover. While Latin America may possess some long-term growth potential, it's hard for investors to see much of a benefit from those operations. And without a breakout or mention of its Latin American operations in its most recent quarterly filings, investors may be surprised to know that UnitedHealth even had a presence in that part of the world. Now, it's reportedly looking at a deal worth $1 billion to offload Banmedica and to cut its losses there. UnitedHealth generates more than $400 billion in annual revenue, and while Latin America may have presented an appealing growth opportunity, it was by no means core to its operations. Right now, its focus is on cutting costs and improving its financial position. Getting rid of an unprofitable investment can be a good way to do that. Costs have been rising for UnitedHealth in recent years, and its profit margin is slim at around 5% of revenue. In previous years, it may have been more tenable to absorb the losses in exchange for future growth opportunities. But as the business has come under pressure and its financials have been falling short of analyst expectations in recent quarters, that may simply no longer be the case. Back in April, UnitedHealth slashed its guidance for the year, projecting its adjusted per-share earnings to come in between $26 and $26.50, down significantly from its previous forecast of $29.50 to $30. Exiting Latin America isn't going to suddenly fix its problems, but it's potentially a step in the right direction by focusing on cost-cutting measures to improve its financials. UnitedHealth Group isn't doing well and is now trading around its five-year lows. The stock has tumbled significantly and after the recent resignation of CEO Andrew Witty, it's now Stephen Hemsley who is once again leading the business (he previously served as CEO from 2006 to 2017). What's encouraging is that the company is still targeting a long-run growth rate of 13% to 16%, suggesting that management believes there is a path to steer the business in the right direction, despite all the adversity it's facing right now. Currently, shares of UnitedHealth Group trade at around 13 times trailing earnings, which can give investors a fairly good discount; the average S&P 500 stock trades at an earnings multiple of nearly 24. At such a steep reduction, investors are getting a good margin of safety with UnitedHealth Group stock today, and it can make for an attractive long-term buy -- as long as you're willing to be patient with it. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. UnitedHealth Group Looks to Exit Latin America. Is This a Good Move for Investors, or a Sign of More Problems Ahead? was originally published by The Motley Fool
